Cas:33575-81-4 2-(Chloromethyl)-5-(3,4-dichlorophenyl)-1,3,4-oxadiazole manufacturer & supplier

Chemical Name:2-(Chloromethyl)-5-(3,4-dichlorophenyl)-1,3,4-oxadiazole

CAS.NO:33575-81-4

Synonyms:2-(chloromethyl)-5-(3,4-dichlorophenyl)-1,3,4-oxadiazole

Molecular Formula:C₉H₅Cl₃N₂O

Molecular Weight:263.50800

HS Code:2934999090

Physical and Chemical Properties:

Melting point:120-122ºC

Boiling point:382.6ºC at 760mmHg

Density:1.5g/cm3

Index of Refraction:1.585

PSA:38.92000

Exact Mass:261.94700

LogP:3.78220

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-(chloromethyl)-5-(3,4-dichlorophenyl)-1,3,4-oxadiazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(chloromethyl)-5-(3,4-dichlorophenyl)-1,3,4-oxadiazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(chloromethyl)-5-(3,4-dichlorophenyl)-1,3,4-oxadiazole Use and application,2-(chloromethyl)-5-(3,4-dichlorophenyl)-1,3,4-oxadiazole technical grade,usp/ep/jp grade.

Related News: Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study. 2-(Chloromethyl)-5-(3,4-dichlorophenyl)-1,3,4-oxadiazole manufacturer The entire set of results “strongly support” the Darzalex-Rd combo as a new standard of care for newly diagnosed, transplant-ineligible multiple myeloma patients, Thierry Facon, M.D., an investigator of the MAIA trial, said in a statement. 2-(Chloromethyl)-5-(3,4-dichlorophenyl)-1,3,4-oxadiazole supplier As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. 2-(Chloromethyl)-5-(3,4-dichlorophenyl)-1,3,4-oxadiazole vendor The entire set of results “strongly support” the Darzalex-Rd combo as a new standard of care for newly diagnosed, transplant-ineligible multiple myeloma patients, Thierry Facon, M.D., an investigator of the MAIA trial, said in a statement. 2-(Chloromethyl)-5-(3,4-dichlorophenyl)-1,3,4-oxadiazole factory As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy.